Financings

NewLink Genetics Corp. filed to raise up to $86 million in an initial public offering.

NovImmune SA added $20.6 million to last year's $56.5 million Series B financing.

Ventrus Biosciences Inc. raised $17.4 million in its initial public offering.

Deals

Arresto Biosciences Inc. is being acquired by Gilead Sciences Inc. for $225 million.

Avila Therapeutics Inc. signed an $810 million covalent drug discovery deal with Sanofi-Aventis SA.

Neurimmune Holding AG sold three preclinical neurology programs to Biogen Idec Inc. for $427 million.

Emisphere Technologies Inc. signed a $57.5 million oral insulin deal with Novo Nordisk A/S.

EpiTherapeutics Aps partnered with Abbott to discover epigenetic oncology inhibitors (no terms).

LPath Inc. entered a $500M option deal with Pfizer Inc. for antibodies in oncology and ophthalmology.

Nymox Pharmaceutical Corp. inked a European deal with Recordati SpA for Phase III BPH drug NX-1207

Oncolys BioPharma Inc. sold its Phase II HIV drug to Bristol-Myers Squibb Co. for $286 million.

Phylogica Ltd. inked a $134 million peptide vaccine discovery deal with Pfizer Inc.

. . . And More

Adolor Corp.'s delta opioid receptor agonist program was dropped by partner Pfizer Inc.

AstraZeneca plc got an FDA complete response letter for antiplatelet drug Brilinta (ticagrelor).

Chelsea Therapeutics International Ltd. said the FDA is not requiring additional efficacy studies for hypotension drug Northera (droxidopa).

Corcept Therapeutics Inc.'s Corlux (mifepristone) had good data in a Phase III Cushing's syndrome trial.

Incyte Corp.'s INCB18424 reduced spleen size in a Phase III myelofibrosis trial.

InterMune Inc.'s IPF drug pirfenidone got a positive opinion from European regulatory advisors.

Regeneron Pharmaceuticals Inc.'s aflibercept met its endpoint in a Phase III trial for macular edema due to central retinal vein occlusion.